mtp

MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation. Further, it inhibits JAK2 signaling, rendering it useful for the study of oral squamous cell carcinoma [1].

Dirlotapide (CP742033) is an intestinal selective microsomal triglyceride transfer protein (MTP) inhibitor. It reduces body weight in diabetic dogs.Dirlotapide reduces food intake in a dose-dependent manner, possibly by increasing the release of peptide YY into the circulation.

MTP 131 is a mitochondria-targeted peptide antioxidant.1,2It localizes to the mitochondria and reducestert-butyl hydroperoxide-induced lipid peroxidation and apoptosis in SH-SY5Y cells when used at concentrations ranging from 0.001 to 1 nM.1MTP 131 (2 mg kg) reduces infarct volume, hemispheric swelling, and glutathione (GSH) depletion in a mouse model of acute cerebral ischemia induced by middle cerebral artery occlusion (MCAO).2It increases survival, improves motor function, and decreases degeneration of the lumbar spinal cord in a superoxide dismutase 1 mutant (SOD1G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS) when administered at a dose of 5 mg kg. MTP 131 reduces albuminuria, urinary hydrogen peroxide levels, and mesangial matrix accumulation, as well as preserves superoxide production, in adb dbmouse model of diabetic nephropathy.3 1.Zhao, K., Luo, G., Giannelli, S., et al.Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell linesBiochem. Pharmacol.70(12)1796-1806(2005) 2.Szeto, H.H.Mitochondria-targeted peptide antioxidants: Novel neuroprotective agentsAAPS J.8(3)E521-E531(2006) 3.Miyamoto, S., Zhang, G., Hall, D., et al.Restoring mitochondrial superoxide levels with elamipretide (MTP-131) protects db db mice against progression of diabetic kidney diseaseJ. Biol. Chem.295(21)7249-7260(2020)

MTPPA (M 5011) is treating inflammation and pain.

Group II/group III metabotropic glutamate receptor antagonist

IMTPPE inhibits transcriptional activity and protein level of AR in C4-2 prostate cancer cells. It also inhibits AR-target gene expression.

Elamipretide (MTP-131) is a mitochondria-targeted antioxidant tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that reduces toxic reactive oxygen species (ROS) production and stabilizes cardiolipin, with blood-brain-barrier permeability. It is a potential therapeutic agent in the rare disease of Barnes syndrome.

Granotapide is a microsomal triglyceride transfer protein (MTP) inhibitor that treats and rather prevents atherosclerosis, coronary artery disease, metabolic syndrome, obesity, diabetes mellitus, prediabetes mellitus, and hypertension.

BMS-212122 (UNII-0Z473OO6GB) is a potent inhibitor of microsomal triglyceride transfer protein (MTP) and has shown hypolipidemic effects in animal studies.BMS-212122 significantly reduced lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques.

Lomitapide (AEGR-733) is a small molecule inhibitor of microsomal triglyceride transfer protein (MTP), an enzyme located in the lumen of the endoplasmic reticulum responsible for absorbing dietary lipids and transferring triglycerides onto apolipoprotein B (apo-B) in the assembly of very-low-density lipoprotein.

Mifamurtide is a drug against osteosarcoma, is an immunomodulator with antitumor effects.

Elamipretide TFA (RX-31 TFA) is a cardiolipin peroxidase inhibitor and mitochondria-targeting peptide[1].

Elamipretide 2TFA (RX-31 2TFA) is a novel mitochondrion-targeted antioxidant.

KD-026 (SLx 4090), a microsomal triglyceride transfer protein (MTP) inhibitor(IC50 = 8.0 nM), is used in type 2 diabetes studies.

Mifamurtide protects mice against herpes simplex virus type 2. It also is a macrophage activator.

CP-346086 is a highly potent and orally bioavailable inhibitor of microsomal triglyceride transfer protein (MTP), exhibiting an IC50 value of 2.0 nM against both human and rodent MTP. This compound effectively reduces plasma levels of cholesterol and triglycerides when administered in vivo.

PF-02575799 is an inhibitor of microsomal triglyceride transfer protein (MTP) (IC50: 0.77±0.29 nM).

Lomitapide Mesylate (BMS-201038 mesylate) is a methanesulfonic acid form of lomitapide, a small molecule inhibitor of microsomal triglyceride transfer protein.

Mifamurtide sodium is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults. It was approved in Europe in March 2009.

Skeletal muscle-targeted peptide MSP, a muscle-targeting peptide (MTP) composed of seven amino acids (ASSLNIA), selectively binds to various ligands in muscle tissues. This targeting capability makes it a useful tool in researching cardiac and skeletal muscle diseases.

Implitapide Racemate, the racemate of Implitapide, is an inhibitor of microsomal triglyceride transfer protein (MTP).

Mifamurtide TFA (MTP-PE TFA), a muramyl dipeptide (MDP) analog, acts as a nonspecific immunomodulator by activating macrophages and monocytes to stimulate the immune response. As an orphan agent and a specific NOD2 ligand, it is utilized as an insulin sensitizer and holds research potential in osteosarcoma [1][2][3].

Elamipretide acetate (MTP 131 acetate) is a derivative of Elamipretide, a small mitochondria-targeting tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that can be used in studies to reduce the production of toxic reactive oxygen species and stabilize cardiolipin.

Implitapide is an inhibitor of microsomal triglyceride transfer protein (MTP).